RxDoctor Payments Data

Patrick Dillon, MD

Medical Oncology · Charlottesville, VANPI 1952502718

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (53.9%), food and beverage and grants — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Novartis at 53.9% of the total. Reporting peaked in 2022 at $453 and has fallen 82.6% since, to $79 in 2025.

$1,359in general payments, 2019–2025

Across 16 payments — averaging $84.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$732
  • AstraZeneca$250
  • Seagen Inc.$104
  • GSK$87
  • Lilly USA, LLC$79
  • Tesaro, Inc.$76
  • plus $30 from 2 others
$2,576,266in research payments, 2019–2025

Across 345 payments — averaging $7467.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$827K
  • Seagen Inc.$584K
  • AstraZeneca$304K
  • Radius Health, Inc.$238K
  • Tesaro, Inc.$216K
  • Pfizer$189K
  • plus $218K from 7 others

What the payments were for

  • Grants$25018%
  • Food & beverage$34626%
  • Education$302%
  • Other$73254%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis8$732
AstraZeneca1$250
Seagen Inc.1$104
GSK1$87
Lilly USA, LLC1$79
Tesaro, Inc.2$76
Merck1$18
Gilead1$12

How this compares

$1,359 in reported general payments places this provider in the 55th percentile of 95 medical oncology providers in Virginia.

See all medical oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$52,264
Medicare patients
231
Services billed
637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate30$465,259
VerzenioAbemaciclib22$338,963
Letrozole139$3,343
Tamoxifen Citrate43$1,100
Dexamethasone22$368
Venlafaxine Hcl ErVenlafaxine Hcl15$258
Prochlorperazine Maleate20$247
Anastrozole15$227
Ondansetron Hcl26$190
Lidocaine-PrilocaineLidocaine/Prilocaine13$150
Prednisone11$88
Oxycodone Hcl11$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$732$465,25930 claims
Lilly USA, LLCVerzenio$79$338,96322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 95 medical oncology providers in Virginia.

Other medical oncology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →